| Literature DB >> 27896059 |
Ge Zhang1, Louis J Muglia2, Ranajit Chakraborty3, Joshua M Akey4, Scott M Williams5.
Abstract
It has recently been hypothesized that polygenic adaptation, resulting in modest allele frequency changes at many loci, could be a major mechanism behind the adaptation of complex phenotypes in human populations. Here we leverage the large number of variants that have been identified through genome-wide association (GWA) studies to comprehensively study signatures of natural selection on genetic variants associated with complex traits. Using population differentiation based methods, such as FST and phylogenetic branch length analyses, we systematically examined nearly 1300 SNPs associated with 38 complex phenotypes. Instead of detecting selection signatures at individual variants, we aimed to identify combined evidence of natural selection by aggregating signals across many trait associated SNPs. Our results have revealed some general features of polygenic selection on complex traits associated variants. First, natural selection acting on standing variants associated with complex traits is a common phenomenon. Second, characteristics of selection for different polygenic traits vary both temporarily and geographically. Third, some studied traits (e.g. height and urate level) could have been the primary targets of selection, as indicated by the significant correlation between the effect sizes and the estimated strength of selection in the trait associated variants; however, for most traits, the allele frequency changes in trait associated variants might have been driven by the selection on other correlated phenotypes. Fourth, the changes in allele frequencies as a result of selection can be highly stochastic, such that, polygenic adaptation may accelerate differentiation in allele frequencies among populations, but generally does not produce predictable directional changes. Fifth, multiple mechanisms (pleiotropy, hitchhiking, etc) may act together to govern the changes in allele frequencies of genetic variants associated with complex traits.Entities:
Keywords: Complex traits; Genome-wide association; Natural selection; Polygenic adaptation
Year: 2013 PMID: 27896059 PMCID: PMC5121263 DOI: 10.1016/j.atg.2013.10.002
Source DB: PubMed Journal: Appl Transl Genom ISSN: 2212-0661
Fig. 1(A) Population tree (topology) of the nine 1000 Genomes populations.
(B) schematic graph of branch length estimation.
Different measures of differentiation in allele frequencies among populations.
| Measure | Description |
|---|---|
| Global | Global |
| AFR_ASN | Average |
| AFR_EUR | |
| ASN_EUR | |
| AFR | Average |
| ASN | |
| EUR | |
| Branch length | |
| Total | Sum of all branch lengths |
| AFR | Major split to African populations |
| EUA | Major split to Eurasia |
| ASN | Asia split from Eurasia |
| EUR | European split from Eurasia |
| AFRs | Average branch length of Afrian populations |
| ASNs | Average branch length of Asian populations |
| EURs | Average branch length of European populations |
The 38 complex traits/diseases.
| Trait | Total | Selected | Effect | ||||
|---|---|---|---|---|---|---|---|
| records | snps | pubs | records | snps | snps | PMID | |
| Height | 425 | 385 | 19 | 265 | 178 | 167 | 20881960 |
| Body mass index | 112 | 102 | 16 | 64 | 35 | 30 | 20935630 |
| Systolic blood pressure | 30 | 29 | 3 | 25 | 23 | 17 | 21909115 |
| Diastolic blood pressure | 32 | 30 | 3 | 28 | 22 | 16 | 21909115 |
| Cholesterol, total | 67 | 65 | 2 | 61 | 50 | 44 | 20686565 |
| LDL cholesterol | 104 | 76 | 13 | 85 | 36 | 29 | 20686565 |
| HDL cholesterol | 119 | 96 | 12 | 104 | 47 | 44 | 20686565 |
| Triglycerides | 98 | 78 | 11 | 83 | 33 | 30 | 20686565 |
| Urate levels | 70 | 63 | 8 | 32 | 29 | 29 | 23263486 |
| C-reactive protein | 54 | 46 | 8 | 33 | 18 | 17 | 21300955 |
| Adiponectin levels | 48 | 44 | 9 | 28 | 16 | 14 | 22479202 |
| Liver enzyme levels (gamma-glutamyl transferase) | 26 | 26 | 1 | 25 | 25 | 25 | 22001757 |
| Platelet counts | 74 | 70 | 3 | 55 | 53 | 53 | 22139419 |
| Ventricular conduction | 25 | 25 | 1 | 23 | 23 | 23 | 21076409 |
| QT interval | 74 | 68 | 7 | 34 | 18 | 13 | 19305408 |
| Corneal structure | 32 | 31 | 3 | 27 | 27 | 25 | 23291589 |
| Inflammatory bowel disease | 124 | 118 | 4 | 116 | 108 | 107 | 23128233 |
| Crohn's disease | 212 | 172 | 14 | 168 | 95 | 65 | 21102463 |
| Ulcerative colitis | 129 | 101 | 8 | 92 | 57 | 41 | 21297633 |
| Celiac disease | 50 | 43 | 3 | 32 | 27 | 16 | 20190752 |
| Systemic lupus erythematosus | 111 | 90 | 12 | 52 | 29 | 16 | 19838193 |
| Rheumatoid arthritis | 96 | 78 | 14 | 42 | 28 | 15 | 20453842 |
| Psoriasis | 44 | 36 | 7 | 22 | 16 | 7 | 20953190 |
| Multiple sclerosis | 166 | 146 | 15 | 60 | 48 | 45 | 21833088 |
| Type 1 diabetes | 97 | 78 | 10 | 60 | 39 | 8 | 17554260 |
| Primary biliary cirrhosis | 41 | 32 | 4 | 21 | 17 | 14 | 21399635 |
| Vitiligo | 37 | 37 | 6 | 27 | 25 | 12 | 22561518 |
| Type 2 diabetes | 212 | 140 | 34 | 86 | 49 | 21 | 20581827 |
| Coronary heart disease | 150 | 127 | 20 | 55 | 35 | 24 | 21378990 |
| Asthma | 64 | 53 | 23 | 30 | 20 | 10 | 21804548 |
| Parkinson's disease | 84 | 67 | 15 | 32 | 16 | 9 | 21292315 |
| Schizophrenia | 129 | 111 | 28 | 67 | 49 | 9 | 21926974 |
| Bipolar disorder | 128 | 115 | 19 | 56 | 42 | 15 | 21926972 |
| Breast cancer | 76 | 61 | 24 | 33 | 19 | 8 | 20453838 |
| Prostate cancer | 116 | 82 | 21 | 70 | 34 | 9 | 18264097 |
| Colorectal cancer | 66 | 47 | 18 | 27 | 21 | 5 | 20972440 |
| Menarche (age at onset) | 47 | 44 | 5 | 37 | 33 | 33 | 21102462 |
| Menopause (age at onset) | 40 | 34 | 3 | 23 | 18 | 17 | 22267201 |
The number of association records (records), SNPs (snps) and publications (pubs) in GWA catalog.
The number of records and SNPs that passed our selection criteria.
The number of SNPs with effect size information (estimation and direction) and the PMID of the source article.
Empirical p-values of the mean FST and branch length measures estimated from the GWA SNPs.
| Trait | Number of SNPs | Empirical p-values of | Empirical p-values of branch length measures | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global | Average | AFR_ASN AFR_EUR ASN_EUR | AFRs | ASNs | EURs | Total | AFR | EUA | ASN | EUR | AFRs | ASNs | EURs | |||||
| Height | 178 | 167 | 0.0336 | 0.283 | 0.799 | 0.111 | 0.713 | 0.0428 | 0.657 | 0.0808 | 0.664 | 0.1 | 0.713 | |||||
| Body mass index | 35 | 30 | 0.326 | 0.618 | 0.645 | 0.288 | 0.301 | 0.676 | 0.912 | 0.823 | 0.588 | 0.328 | 0.762 | 0.276 | 0.527 | 0.823 | 0.882 | 0.803 |
| Systolic blood pressure | 23 | 17 | 0.341 | 0.608 | 0.77 | 0.446 | 0.141 | 0.771 | 0.877 | 0.27 | 0.686 | 0.715 | 0.315 | 0.05 | 0.646 | 0.787 | ||
| Diastolic blood pressure | 22 | 16 | 0.554 | 0.798 | 0.944 | 0.611 | 0.2 | 0.876 | 0.632 | 0.581 | 0.919 | 0.861 | 0.384 | 0.103 | 0.794 | 0.656 | ||
| Cholesterol, total | 50 | 44 | 0.219 | 0.731 | 0.241 | 0.317 | 0.459 | 0.296 | 0.164 | 0.111 | 0.0964 | 0.425 | 0.435 | 0.599 | 0.419 | 0.163 | ||
| LDL cholesterol | 36 | 29 | 0.679 | 0.807 | 0.541 | 0.773 | 0.471 | 0.128 | 0.089 | 0.953 | 0.678 | 0.439 | 0.738 | 0.552 | 0.596 | 0.2 | 0.148 | 0.986 |
| HDL cholesterol | 47 | 44 | 0.233 | 0.256 | 0.389 | 0.668 | 0.0732 | 0.531 | 0.094 | 0.158 | 0.28 | 0.302 | 0.881 | 0.136 | 0.331 | 0.473 | 0.117 | 0.22 |
| Triglycerides | 33 | 30 | 0.0146 | 0.168 | 0.179 | 0.0382 | 0.409 | 0.0304 | 0.0374 | 0.866 | 0.0386 | 0.0126 | 0.342 | |||||
| Urate levels | 29 | 29 | 0.0226 | 0.117 | 0.073 | 0.0226 | 0.953 | 0.643 | 0.0348 | 0.0204 | 0.266 | 0.357 | 0.0192 | 0.042 | 0.925 | 0.658 | 0.032 | |
| C-reactive protein | 18 | 17 | 0.366 | 0.168 | 0.335 | 0.409 | 0.285 | 0.0294 | 0.325 | 0.0586 | 0.349 | 0.487 | 0.549 | 0.282 | 0.583 | 0.0684 | 0.522 | 0.081 |
| Adiponectin levels | 16 | 14 | 0.887 | 0.971 | 0.629 | 0.992 | 0.679 | 0.496 | 0.88 | 0.26 | 0.929 | 0.9 | 0.877 | 0.667 | 0.761 | 0.446 | 0.692 | 0.177 |
| Ggamma-glutamyl transferase | 25 | 25 | 0.294 | 0.411 | 0.136 | 0.626 | 0.301 | 0.0402 | 0.434 | 0.184 | 0.259 | 0.298 | 0.501 | 0.149 | 0.788 | 0.0714 | 0.377 | 0.218 |
| Platelet counts | 53 | 53 | 0.618 | 0.859 | 0.434 | 0.332 | 0.884 | 0.438 | 0.0784 | 0.277 | 0.348 | 0.0576 | 0.595 | 0.748 | 0.845 | 0.458 | 0.0224 | 0.307 |
| Ventricular conduction | 23 | 23 | 0.772 | 0.827 | 0.904 | 0.717 | 0.653 | 0.149 | 0.239 | 0.109 | 0.787 | 0.841 | 0.813 | 0.768 | 0.532 | 0.137 | 0.165 | 0.113 |
| QT interval | 18 | 13 | 0.294 | 0.23 | 0.904 | 0.0896 | 0.243 | 0.598 | 0.136 | 0.939 | 0.553 | 0.483 | 0.668 | 0.542 | 0.214 | 0.539 | 0.179 | 0.952 |
| Corneal structure | 27 | 25 | 0.37 | 0.32 | 0.36 | 0.324 | 0.45 | 0.516 | 0.777 | 0.336 | 0.517 | 0.268 | 0.439 | 0.659 | 0.286 | 0.808 | ||
| Inflammatory bowel disease | 108 | 107 | 0.122 | 0.122 | 0.232 | 0.127 | 0.33 | 0.237 | 0.15 | 0.164 | 0.089 | 0.0764 | 0.384 | 0.201 | 0.451 | 0.311 | 0.196 | 0.298 |
| Crohn's disease | 95 | 65 | 0.0898 | 0.178 | 0.556 | 0.299 | 0.0188 | 0.197 | 0.113 | 0.032 | 0.131 | 0.643 | 0.935 | 0.0154 | 0.0654 | 0.176 | 0.0824 | 0.18 |
| Ulcerative colitis | 57 | 41 | 0.478 | 0.457 | 0.268 | 0.91 | 0.125 | 0.584 | 0.0608 | 0.58 | 0.437 | 0.641 | 0.84 | 0.0674 | 0.506 | 0.618 | 0.0608 | 0.68 |
| Celiac disease | 27 | 16 | 0.141 | 0.186 | 0.55 | 0.0352 | 0.177 | 0.708 | 0.658 | 0.805 | 0.125 | 0.0622 | 0.566 | 0.123 | 0.215 | 0.649 | 0.723 | 0.825 |
| Systemic lupus erythematosus | 29 | 16 | 0.0554 | 0.0328 | 0.396 | 0.367 | 0.292 | 0.27 | 0.0268 | 0.322 | 0.559 | 0.322 | 0.199 | 0.217 | ||||
| Rheumatoid arthritis | 28 | 15 | 0.399 | 0.415 | 0.264 | 0.719 | 0.299 | 0.375 | 0.0542 | 0.336 | 0.42 | 0.388 | 0.717 | 0.422 | 0.419 | 0.324 | 0.115 | 0.297 |
| Psoriasis | 16 | 7 | 0.0952 | 0.167 | 0.087 | 0.167 | 0.462 | 0.218 | 0.0842 | 0.581 | 0.215 | 0.099 | 0.347 | 0.413 | 0.707 | 0.159 | 0.147 | 0.586 |
| Multiple sclerosis | 48 | 45 | 0.707 | 0.472 | 0.341 | 0.887 | 0.422 | 0.626 | 0.0212 | 0.258 | 0.585 | 0.857 | 0.505 | 0.465 | 0.462 | 0.681 | 0.038 | 0.292 |
| Type 1 diabetes | 39 | 8 | 0.0458 | 0.0994 | 0.528 | 0.0956 | 0.013 | 0.18 | 0.107 | 0.167 | 0.0334 | 0.423 | 0.408 | 0.0918 | 0.0248 | 0.104 | 0.0318 | 0.174 |
| Primary biliary cirrhosis | 17 | 14 | 0.18 | 0.199 | 0.156 | 0.495 | 0.306 | 0.823 | 0.272 | 0.0652 | 0.143 | 0.0694 | 0.777 | 0.08 | 0.742 | 0.78 | 0.18 | 0.0206 |
| Vitiligo | 25 | 12 | 0.0262 | 0.642 | 0.812 | 0.0234 | 0.0394 | 0.955 | 0.197 | 0.269 | 0.344 | 0.0808 | 0.839 | 0.0734 | ||||
| Type 2 diabetes | 49 | 21 | 0.0354 | 0.151 | 0.221 | 0.121 | 0.0894 | 0.508 | 0.32 | 0.332 | 0.0264 | 0.404 | 0.0386 | 0.103 | 0.0672 | 0.354 | 0.395 | 0.279 |
| Coronary heart disease | 35 | 24 | 0.133 | 0.129 | 0.468 | 0.0338 | 0.385 | 0.601 | 0.321 | 0.103 | 0.0712 | 0.0416 | 0.233 | 0.554 | 0.266 | 0.775 | 0.099 | 0.0996 |
| Asthma | 20 | 10 | 0.225 | 0.194 | 0.36 | 0.499 | 0.148 | 0.951 | 0.733 | 0.147 | 0.269 | 0.243 | 0.729 | 0.155 | 0.235 | 0.929 | 0.738 | 0.132 |
| Parkinson's disease | 16 | 9 | 0.804 | 0.899 | 0.918 | 0.571 | 0.556 | 0.763 | 0.288 | 0.0482 | 0.637 | 0.719 | 0.793 | 0.621 | 0.459 | 0.695 | 0.0644 | 0.043 |
| Schizophrenia | 49 | 9 | 0.0164 | 0.0114 | 0.556 | 0.31 | 0.297 | 0.381 | 0.0258 | 0.557 | 0.606 | 0.289 | 0.293 | 0.333 | ||||
| Bipolar disorder | 42 | 15 | 0.63 | 0.595 | 0.758 | 0.707 | 0.448 | 0.348 | 0.144 | 0.0112 | 0.582 | 0.803 | 0.822 | 0.689 | 0.269 | 0.224 | 0.044 | 0.0264 |
| Breast cancer | 19 | 8 | 0.298 | 0.233 | 0.253 | 0.607 | 0.18 | 0.708 | 0.434 | 0.949 | 0.364 | 0.645 | 0.506 | 0.0756 | 0.299 | 0.731 | 0.454 | 0.919 |
| Prostate cancer | 34 | 9 | 0.0174 | 0.0296 | 0.045 | 0.449 | 0.777 | 0.042 | 0.405 | 0.01 | 0.119 | 0.38 | 0.682 | 0.717 | 0.0176 | 0.24 | ||
| Colorectal cancer | 21 | 5 | 0.234 | 0.165 | 0.259 | 0.257 | 0.385 | 0.0662 | 0.096 | 0.0648 | 0.171 | 0.225 | 0.261 | 0.429 | 0.109 | 0.0104 | 0.143 | |
| Menstruation related | ||||||||||||||||||
| Menarche (age at onset) | 33 | 33 | 0.828 | 0.801 | 0.715 | 0.924 | 0.461 | 0.905 | 0.615 | 0.605 | 0.799 | 0.851 | 0.697 | 0.567 | 0.231 | 0.954 | 0.659 | 0.696 |
| Menopause (age at onset) | 18 | 17 | 0.324 | 0.218 | 0.451 | 0.24 | 0.256 | 0.837 | 0.848 | 0.236 | 0.402 | 0.52 | 0.271 | 0.378 | 0.358 | 0.829 | 0.634 | 0.352 |
* Significant p-values (< 0.01) are highlighted in bold.
List of GWA SNPs with top significant signals of accelerated differentiation.
Note: SNPs in close LD are highlighted in gray blocks. Significant iHS scores (|iHS| > 2.0) are printed in bold.
Fig. 2Distributions of the global FST (left) and the total branch length (right) estimated from the height GWA SNPs (red) in contrast to genome background (blue).
Fig. 3Box plots of mean FST estimated from the randomly selected permutation sets of SNPs (genome background) and the mean FST estimated from the height GWA SNPs (red dots). The numbers in parentheses are the empirical p-values.
Fig. 4Box plots of mean branch lengths estimated by either OLS (top) or ML (bottom) from the randomly selected permutation sets of SNPs (genome background) and the mean branch lengths estimated from the height GWA SNPs (red dots). The numbers in parentheses are the empirical p-values.
Fig. 5Dot plots between the allele frequency adjusted effect size and the global FST (left) or total branch length (right) of the height GWA SNPs.
Fig. 6Frequency distributions of derived alleles (blue: alleles with positive effect; red: alleles with negative effect) of the height GWA SNPs in the three continental populations. The numbers of derived alleles with positive (+) or negative (−) effect and the Wilcoxon test p-values (in parentheses) are shown above the figures.